- Home
- ROIV vs EXLS Comparison
ROIV vs EXLS Comparison
Compare ROIV & EXLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROIV
- EXLS
- Stock Information
- Founded
- ROIV 2014
- EXLS 1999
- Country
- ROIV United Kingdom
- EXLS United States
- Employees
- ROIV N/A
- EXLS N/A
- Industry
- ROIV Biotechnology: Pharmaceutical Preparations
- EXLS Business Services
- Sector
- ROIV Health Care
- EXLS Consumer Discretionary
- Exchange
- ROIV Nasdaq
- EXLS Nasdaq
- Market Cap
- ROIV 8.6B
- EXLS 6.5B
- IPO Year
- ROIV N/A
- EXLS 2006
- Fundamental
- Price
- ROIV $19.86
- EXLS $39.56
- Analyst Decision
- ROIV Strong Buy
- EXLS Strong Buy
- Analyst Count
- ROIV 8
- EXLS 4
- Target Price
- ROIV $21.06
- EXLS $54.50
- AVG Volume (30 Days)
- ROIV 8.1M
- EXLS 1.5M
- Earning Date
- ROIV 11-10-2025
- EXLS 10-28-2025
- Dividend Yield
- ROIV N/A
- EXLS N/A
- EPS Growth
- ROIV N/A
- EXLS 29.94
- EPS
- ROIV N/A
- EXLS 1.48
- Revenue
- ROIV $23,233,000.00
- EXLS $2,026,490,000.00
- Revenue This Year
- ROIV N/A
- EXLS $14.78
- Revenue Next Year
- ROIV $320.50
- EXLS $11.33
- P/E Ratio
- ROIV N/A
- EXLS $26.72
- Revenue Growth
- ROIV N/A
- EXLS 14.43
- 52 Week Low
- ROIV $8.73
- EXLS $37.30
- 52 Week High
- ROIV $20.09
- EXLS $52.43
- Technical
- Relative Strength Index (RSI)
- ROIV 79.61
- EXLS 40.09
- Support Level
- ROIV $19.30
- EXLS $38.20
- Resistance Level
- ROIV $20.09
- EXLS $40.73
- Average True Range (ATR)
- ROIV 0.57
- EXLS 1.07
- MACD
- ROIV 0.11
- EXLS -0.12
- Stochastic Oscillator
- ROIV 92.97
- EXLS 48.35
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About EXLS ExlService Holdings Inc.
ExlService Holdings Inc. is a business process management company that provides digital operations and analytical services to clients driving enterprise-scale business transformation initiatives that leverage the company's deep expertise in analytics, AI, ML, and cloud. The company offers business process outsourcing and automation services, and data-driven insights to customers across multiple industries. The company operates through four segments based on the products and services offered and markets served: Insurance, Healthcare, Emerging Business, and Analytics . The vast majority of the company's revenue is earned in the United States, and more than half of its revenue comes from Analytics segment.